Working... Menu

Myo-inositol Plus Melatonin in Perimenopausal Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01325389
Recruitment Status : Unknown
Verified March 2011 by AGUNCO Obstetrics and Gynecology Centre.
Recruitment status was:  Recruiting
First Posted : March 29, 2011
Last Update Posted : March 29, 2011
Information provided by:
AGUNCO Obstetrics and Gynecology Centre

Brief Summary:

Menopause is the milestone of a more broaden condition that can last up to 10 years. The first menopausal symptoms usually appear around the age of 42 and are characterized by a gradual decline in thyroid and gonadal function with a progressive increase of plasmatic luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels.

Recent studies have shown that myo-inositol and melatonin play a major role in ovarian homeostasis. In particular, it has been demonstrated that myo-inositol and/or melatonin supplementation lead to an increase of oocyte quality.

Additional studies focused on postmenopausal women have shown that myo-inositol is able to ameliorate the metabolic syndrome that often affects these patients, thus reducing the risk of cardiovascular diseases (CVDs).

The aim of the present study is to evaluate whether myo-inositol and melatonin might play a positive role in regulating hormonal levels during menopausal onset.

Condition or disease Intervention/treatment Phase
Perimenopause Dietary Supplement: Myo-Mel Dietary Supplement: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Effects of Myo-inositol Plus Melatonin in Perimenopausal Women

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Myo+Mel
Patients are treated with 2g of myo + 3mg of melatonin daily
Dietary Supplement: Myo-Mel
Placebo Comparator: Placebo Dietary Supplement: Placebo

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   42 Years to 48 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • FSH between 15 and 50 IU/ml on the 5th day of the menses
  • Oligomenorrhea

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01325389

Layout table for location information
AGUNCO Recruiting
Rome, Italy, 00155
Contact: Gianfranco Carlomagno, Ph.D.   
Principal Investigator: Gianfranco Carlomagno, Ph.D         
Principal Investigator: Vittorio Unfer, M.D.         
Sponsors and Collaborators
AGUNCO Obstetrics and Gynecology Centre


Layout table for additonal information Identifier: NCT01325389     History of Changes
Other Study ID Numbers: Myo+MEL_peri_women
First Posted: March 29, 2011    Key Record Dates
Last Update Posted: March 29, 2011
Last Verified: March 2011

Additional relevant MeSH terms:
Layout table for MeSH terms
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Central Nervous System Depressants
Vitamin B Complex
Growth Substances